Buy Park Medi World Ltd for the Target Rs 350 by Emkay Global Financial Services Ltd
We initiate coverage on Park Medi World (Park) with BUY and Mar-27E TP of Rs350 (37% upside), based on 21x Mar-28E EBITDA (in line with sector average). Park’s differentiated business model and lean cost structure allow it to deliver quality care at accessible prices. This helps unlock mass-market volumes that maximize asset utilization, creating a flywheel of profitability and optimized return ratios. Leveraging its technocrat promoters’ expertise and cluster-based regional strategy, Park has steadfastly become the secondlargest chain by bed capacity in North India. The management’s demonstrated execution prowess and ability to turn around acquisitions (often sick units) are validated with such units contributing ~62% to FY26 EBITDA. This agility allows for rapid scale without compromising on capex discipline. With a robust pipeline (~2,200 beds identified; ~60% of FY26 capacity) and a strategic roadmap to enter high-demand, underpenetrated markets such as UP, we expect Park to clock 24%/23% revenue/EBITDA CAGR over FY26-29. Strong balance sheet (net cash of Rs2bn), healthy cash conversion (FY26 OCF/EBITDA: 74%), and improving working capital cycle should drive a re-rating.
Park’s differentiated value proposition addresses mass-market needs
Park boasts one of the lowest capex spends/bed (Rs3.2mn) in the industry. This stems from
i) Its ability to design hospitals that optimize space used per bed (0.6x of industry average)
ii) Its mass market appeal (higher volumes) allowing better asset utilization (~50% higher vs industry average). Park’s ‘cluster-based’ model of expansion aids shared use of clinical talent (doctor fees 15% of sales vs 20% industry average), higher IP/OP conversion (11% vs 8%), and economies of scale (consumables, outsourced manpower), allowing it to deliver top-decile margins despite lower ARPOB vs peers’
Potent mix of quality, affordability, and scalability
While peer hospital chains focus on providing premium quaternary care, Park strategically targets serving the underserved middle and bottom-of-the-demographic pyramid. Its proven ability to turn around multiple inefficient assets (with a core-cluster TAM of ~14k mid-size hospitals) provides a strong foundation for accelerated expansion. As the company scales toward its 10k-bed target over the next 5Y, operating leverage should drive meaningful margin improvement – sustaining Park's growth ambitions, in our view.
Initiate with BUY and Mar-27E TP of Rs350
With bed capacity slated to almost double over FY26-29E, we expect Park to log revenue CAGR of 24% over this period. While historically, Park has stuck with the absolute ownership model, its foray into UP on the back of an asset-light strategy (O&M) should limit execution risks and set the foundation for the next leg of value-accretive growth. We thus expect EBITDA CAGR of 23% as operating leverage, CGHS price hike benefits, and improving payor mix offset the drag from new unit adds. Risks: Execution challenges in ramping up new units, delays in collections from government-scheme patients.
For More Emkay Global Financial Services Ltd Disclaimer http://www.emkayglobal.com/Uploads/disclaimer.pdf & SEBI Registration number is INH000000354
